The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Open accessAbstract
The sedative and anti-nausea drug thalidomide, which causes birth defects in humans, has been shown to have both anti-inflammatory and anti-oncogenic properties. The anti-inflammatory effect of thalidomide is associated with suppression of cytokine expression and the anti-oncogenic effect with inhibition of angiogenesis. It is presently unclear whether the teratogenic properties of thalidomide are connected in any way to the beneficial, anti-disease characteristics of this drug. The transcription factor NF-kappaB has been shown to be a key regulator of inflammatory genes such as tumor necrosis factor-alpha and interleukin-8. Inhibition of NF-kappaB is associated with reduced inflammation in animal models, such as those for rheumatoid arthritis. We show here that thalidomide can block NF-kappaB activation through a mechanism that involves the inhibition of activity of the IkappaB kinase. Consistent with the observed inhibition of NF-kappaB, thalidomide blocked the cytokine-induced expression of NF-kappaB-regulated genes such as those encoding interleukin-8, TRAF1, and c-IAP2. These data indicate that the therapeutic potential for thalidomide may be based on its ability to block NF-kappaB activation through suppression of IkappaB kinase activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
Barnes, P. J., & Karin, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361506 · Cited by 4,669
Multiple nuclear factors interact with the immunoglobulin enhancer sequences
Sen, R., & Baltimore, D. (1986) · Cell · doi:10.1016/0092-8674(86)90346-6 · Cited by 2,752
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135
A cytokine-responsive IκB kinase that activates the transcription factor NF-κB
DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., & Karin, M. (1997) · Nature · doi:10.1038/41493 · Cited by 2,125
IKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation
Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J. W., Young, D. B., Barbosa, M., Mann, M., Manning, A., et al. (1997) · Science · doi:10.1126/science.278.5339.860 · Cited by 2,040
Permanent cell line expressing human factor VIII-related antigen established by hybridization.
Edgell, C. J., McDonald, C. C., & Graham, J. B. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.12.3734 · Cited by 1,488
NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
Self-citationSampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
How NF-κB is activated: the role of the IκB kinase (IKK) complex
Karin, M. (1999) · Oncogene · doi:10.1038/sj.onc.1203219 · Cited by 1,156
Signal transduction through NF-κB
May, M. J., & Ghosh, S. (1998) · Immunology Today · doi:10.1016/s0167-5699(97)01197-3 · Cited by 1,091
A short history of thalidomide embryopathy
Lenz, W. (1988) · Teratology · doi:10.1002/tera.1420380303 · Cited by 784
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Yoshida, S., Ono, M., Shono, T., Izumi, H., Ishibashi, T., Suzuki, H., & Kuwano, M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.4015 · Cited by 696
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
The Beginning of the End: IκB Kinase (IKK) and NF-κB Activation
Karin, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27339 · Cited by 640
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
Multiple signals converging on NF-κB
Mercurio, F., & Manning, A. M. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80030-1 · Cited by 473
TNF-Induced Signaling in Apoptosis
Rath, P. C., & Aggarwal, B. B. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020546615229 · Cited by 462
Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization
KENYON, B. M., BROWNE, F., & D'AMATO, R. J. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0292 · Cited by 440
Sampaio, E. P., Kaplan, G., Miranda, A., Nery, J. A. C., Miguel, C. P., Viana, S. M., & Sarno, E. N. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/168.2.408 · Cited by 366
Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M. M., Pyle, L., Johnston, S. R. D., Ahern, R., Smith, I. E., & Gore, M. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1004 · Cited by 338
IκB proteins: structure, function and regulation
Whiteside, S. T., & Israël, A. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0058 · Cited by 324
Thalidomide: current and potential clinical applications
Calabrese, L., & Fleischer, A. B. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00408-8 · Cited by 324
IκB kinase: Beginning, not the end
Verma, I. M., & Stevenson, J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.11758 · Cited by 198
Pazin, M. J., Sheridan, P. L., Cannon, K., Cao, Z., Keck, J. G., Kadonaga, J. T., & Jones, K. A. (1996) · Genes & Development · doi:10.1101/gad.10.1.37 · Cited by 186
Stylianou, E., & Saklatvala, J. (1998) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(98)00081-8 · Cited by 185
Cheshire, J. L., & Baldwin, A. S. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6746 · Cited by 178
McBride, W. G. (1977) · Teratology · doi:10.1002/tera.1420160113 · Cited by 138
Thalidomide as an emerging immunotherapeutic agent
Marriott, J. B., Muller, G. W., & Dalgleish, A. G. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01531-5 · Cited by 123
Thalidomide Inhibits Angiogenesis in Embryoid Bodies by the Generation of Hydroxyl Radicals
Sauer, H., Günther, J., Hescheler, J., & Wartenberg, M. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64714-1 · Cited by 115
Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages
Tavares, J. L., Wangoo, A., Dilworth, P., Marshall, B. G., Kotecha, S., & Shaw, R. J. (1997) · Respiratory Medicine · doi:10.1016/s0954-6111(97)90134-7 · Cited by 107
Thalidomide and a Thalidomide Analogue Inhibit Endothelial Cell Proliferation in vitro
Moreira, A. L., Friedlander, D. R., Shif, B., Kaplan, G., & Zagzag, D. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006202700039 · Cited by 91
Thalidomide and Thalidomide Analogs Reduce HIV Type 1 Replication in Human Macrophages in Vitro
Moreira, A. L., Corral, L. G., Ye, W., JOHNSON, B., STIRLING, D., Muller, G. W., Freedman, V. H., & Kaplan, G. (1997) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1997.13.857 · Cited by 76
The effect of thalidomide on experimental tumors and metastases
Minchinton, A. I., Fryer, K. H., Wendt, K. R., Clow, K. A., & Hayes, M. M. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199605000-00015 · Cited by 75
Thalidomide on the comeback trail
Hales, B. F. (1999) · Nature Medicine · doi:10.1038/8371 · Cited by 70
Thalidomide in dermatology. New indications for an old drug
Calderón, P., Anzilotti, M., & Phelps, R. G. (1997) · International Journal of Dermatology · doi:10.1046/j.1365-4362.1997.00298.x · Cited by 57
Schuler, U. S., & Ehninger, G. (1995) · Drug Safety · doi:10.2165/00002018-199512060-00002 · Cited by 50
Neutrophils isolated from leprosy patients release TNF-α and exhibit accelerated apoptosis in vitro
de Oliveira, R. B., Moraes, M. O., Oliveira, E. B. D. S., Sarno, E. N., Nery, J. A. C., & Sampaio, E. P. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.3.364 · Cited by 47
Kr�ger, H., Miesel, R., Dietrich, A., Ohde, M., Rajnav�lgyi, E., & Ockenfels, H. (1996) · Inflammation · doi:10.1007/bf01487406 · Cited by 37
Thalidomide: lack of mutagenic activity across phyla and genetic endpoints
Ashby, J., Tinwell, H., Callander, R. D., Kimber, I., Clay, P., Galloway, S. M., Hill, R., Greenwood, S. K., Gaulden, M. E., Ferguson, M. J., et al. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00174-7 · Cited by 35
Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis
Oliver, S. J., Freeman, S. L., Corral, L. G., Ocampo, C. J., & Kaplan, G. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.01039.x · Cited by 29
Joussen, A. M., Germann, T., & Kirchhof, B. (1999) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s004170050330 · Cited by 27
Hauschild, A., KROEGER, H., Mitchison, N. A., et al. (1997) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1997.3781274.x · Cited by 20
Cited by
NF-κB in biology and targeted therapy: new insights and translational implications
Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01757-9 · Cited by 2,047
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
Tisdale, M. J. (2009) · Physiological Reviews · doi:10.1152/physrev.00016.2008 · Cited by 1,192
NF-kB in development and progression of human cancer
Dolcet, X., Llobet, D., Pallares, J., & Matias-Guiu, X. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1264-9 · Cited by 1,169
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,061
Metadata
- Authors
- Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-06
- Volume
- 276
- Issue
- 25
- Pages
- 22382-22387
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2067161281
- Cited by
- 478
- References
- 49
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.